New LCD expanding coverage for prostate cancer patientsMay 25, 2022 This is an important victory for our prostate cancer patients, literally tens of thousands of whom reside in MAC regions which generally follow MolDx guidance in determining coverage. We are grateful to MolDx for their recognition of the value that these tests provide, both in counseling and treatment guidance for our individual patients and, in some cases, as possible education and screening opportunities for related family members. MolDx has demonstrated acumen in this evolving milieu by outlining recommendations which accord to NCCN guidelines, thereby expanding the list of genes eligible for coverage well beyond the very limited panel previously specified for coverage (BRCA1/BRCA2/+/-PALB2). A worksheet detailing additional coverage details is available here. More than half of the Medicare Administrative Contractors in the United States adopt MolDx recommendations, and we can anticipate modification of their LCDs to reflect the updated guidance. LUGPA applauds MolDx for taking the lead nationally on this issue and sincerely thank our Health Policy Committee, legal counsel, advisors, and coalition of aligned stakeholders whose collaborative efforts made this possible. See also
|